3-cyano-3-hydroxy-8-benzyl-8-azabicyclo<3.2.1>octane | 128200-43-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 3-cyano-3-hydroxy-8-benzyl-8-azabicyclo<3.2.1>octane
• 英文别名: 3β-cyano-3α-hydroxy-8-benzyl-8-azabicyclo[3.2.1]octane；3α-cyano-3β-hydroxy-8-benzyl-8-azabicyclo-[3.2.1.]-octane；8-Benzyl-3-hydroxy-8-azabicyclo[3.2.1]octane-3-carbonitrile
• CAS: 128200-43-1；128200-44-2
• 化学式: C₁₅H₁₈N₂O
• 分子量: 242.321
• InChiKey: SJAMZTAPGXASDJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  47.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-cyano-3-hydroxy-8-benzyl-8-azabicyclo<3.2.1>octane 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 反应 0.5h， 生成 3α-(aminomethyl)-3β-hydroxy-8-benzyl-8-azabicyclo<3.2.1>octane
  参考文献：
  名称：

  Novel 5-HT3 antagonists: indol-3-ylspiro(azabicycloalkane-3,5'(4'H)oxazoles)

  摘要：

  The synthesis and biochemical evaluation of a series of spirofused indole oxazoline 5-HT3 antagonists is described in which the oxazoline ring acts as a bioisosteric replacement for esters and amides. The effect of substitution about the indole ring has shown the steric limitations of the aromatic binding site. Incorporation of a variety of azabicyclic systems within the rigid spirofused framework has allowed the definition of a binding model which incorporates a number of known antagonists and agonists. In this model steric constraints limit substitution around the indole ring although there is some bulk tolerance at the 1- and 2-positions. The importance of constraining the basic nitrogen within an azabicyclic system is underlined by comparison with the monocyclic piperidine. The highest affinity was observed for those compounds in which the basic nitrogen occupies a bridgehead position, the most potent analogue in this group being the azabicyclic [3.3.1] system (pIC50 = 8.95), suggesting lipophilic interactions may play a role in increasing affinity. A suggested model for agonist binding is included in which the basic nitrogens are superimposed and the 5-hydroxyl group of 5-HT is superimposed on the H-bond-accepting atom of the heterocyclic linking group.

  DOI：

  10.1021/jm00084a007
• 作为产物：
  描述：

  氰化钠 、 8-(苯基甲基)-8-氮杂双环[3.2.1]辛-3-酮盐酸盐 以 水 为溶剂， 反应 2.0h， 生成 3-cyano-3-hydroxy-8-benzyl-8-azabicyclo<3.2.1>octane
  参考文献：
  名称：

  Novel 5-HT3 antagonists: indol-3-ylspiro(azabicycloalkane-3,5'(4'H)oxazoles)

  摘要：

  The synthesis and biochemical evaluation of a series of spirofused indole oxazoline 5-HT3 antagonists is described in which the oxazoline ring acts as a bioisosteric replacement for esters and amides. The effect of substitution about the indole ring has shown the steric limitations of the aromatic binding site. Incorporation of a variety of azabicyclic systems within the rigid spirofused framework has allowed the definition of a binding model which incorporates a number of known antagonists and agonists. In this model steric constraints limit substitution around the indole ring although there is some bulk tolerance at the 1- and 2-positions. The importance of constraining the basic nitrogen within an azabicyclic system is underlined by comparison with the monocyclic piperidine. The highest affinity was observed for those compounds in which the basic nitrogen occupies a bridgehead position, the most potent analogue in this group being the azabicyclic [3.3.1] system (pIC50 = 8.95), suggesting lipophilic interactions may play a role in increasing affinity. A suggested model for agonist binding is included in which the basic nitrogens are superimposed and the 5-hydroxyl group of 5-HT is superimposed on the H-bond-accepting atom of the heterocyclic linking group.

  DOI：

  10.1021/jm00084a007

文献信息

• Spirocyclic compounds incorporating five-membered rings with two heteroatoms
  申请人：MERCK SHARP & DOHME LTD.

  公开号：EP0337547A1

  公开（公告）日：1989-10-18

  The present invention provides a compound of formula I or a salt or prodrug thereof: wherein the dotted line represents an optional chemical bond in one of the two possible positions; A represents a group of formula II: in which R1 represents hydrogen, hydroxy, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, benzyloxy, hydroxy(C1-6)alkyl, halogen, amino, cyano, nitro, -CONR6R7 or -S02NR6R7, in which R6 and R7 independently represent hydrogen, C1-6 alkyl, C2-6 alkenyl or C2-6 alkynyl; R2 represents hydrogen, halogen, C1 -6 alkyl, C1 -6 alkoxy or C1-6 alkylcarbonyl; V represents nitrogen, -CH or -C-; and W represents oxygen, sulphur or -NR8, in which R8 represents hydrogen, C, -6 alkyl, C2-6 alkenyl or C2-6 alkynyl; two of X, Y and Z are the same or different and each represents oxygen, sulphur or nitrogen; and the remaining group X, Y or Z is carbon, or Y is carbonyl (C = 0); and Q is the residue of an azacyclic or azabicyclic ring system; which compounds are useful in the treatment of psychotic disorders (e.g. schizophrenia and mania); anxiety; alcohol or drug withdrawal or,dependence; pain; gastric stasis; gastric dysfunction (such as occurs with dyspepsia, peptic ulcer, reflux oesophagitis and flatulence); migraine, nausea and vomiting; moyement disorders; and presenile and senile dementia,

  本发明提供一种式 I 的化合物或其盐或原药： 其中虚线代表两个可能位置之一的任选化学键；A 代表式 II 的基团： 其中 R1 代表氢、羟基、C1-6 烷基、C2-6 烯基、C2-6 烷炔基、C1-6 烷氧基、苄氧基、羟基（C1-6）烷基、卤素、氨基、氰基、硝基、-CONR6R7 或 -S02NR6R7，其中 R6 和 R7 独立地代表氢、C1-6 烷基、C2-6 烯基或 C2-6 烷炔基； R2 代表氢、卤素、C1-6 烷基、C1-6 烷氧基或 C1-6 烷基羰基； V 代表氮、-CH 或-C-；以及 W 代表氧、硫或-NR8，其中 R8 代表氢、C, -6 烷基、C2-6 烯基或 C2-6 烷炔基； X、Y 和 Z 中的两个相同或不同，各自代表氧、硫或氮；其余基团 X、Y 或 Z 为碳，或 Y 为羰基（C = 0）；以及 Q 是氮杂环或氮双环环系统的残基；这些化合物可用于治疗精神病（如精神分裂症和躁狂症）、焦虑症、酒精或药物戒断或依赖症、疼痛、胃淤血、胃功能障碍（如消化不良、消化性溃疡、反流性食管炎和胀气）、偏头痛、恶心和呕吐、精神错乱以及先天性和老年性痴呆症、
• US4940703A
  申请人：——

  公开号：US4940703A

  公开（公告）日：1990-07-10